BioMarin Pharmaceutical Inc. BMRN
57.13 USD -0.05 (-0.09%)
At closeNov 11, 2026, 6:07 AM EST
57.30 +0.17 +0.30%
Pre-market · Nov 11, 6:07 AM ET
56.38 Day range 57.37
49.26 52-week range 70.98
- YTD
- -3.87%
- 1 year
- +8.47%
News
defenseworld.net Bfsg LLC Buys 17,538 Shares of BioMarin Pharmaceutical Inc. $BMRN Bfsg LLC acquired a new position in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) in the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor…
defenseworld.net Traders Buy Large Volume of BioMarin Pharmaceutical Call Options (NASDAQ:BMRN) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,961 call options on the stock. This is an…
benzinga.com JP Morgan Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $86 JP Morgan analyst Jessica Fye maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $87 to $86.
seekingalpha.com BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a…
prnewswire.com BioMarin to Participate in Upcoming Investor Conferences Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL,…
benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $119 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $122 to $119.
benzinga.com Oppenheimer Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $94 Oppenheimer analyst Leland Gershell maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price target from $97 to $94.- benzinga.com HC Wainwright & Co. Reiterates Neutral on BioMarin Pharmaceutical, Maintains $60 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Neutral and maintains $60 price target.
benzinga.com RBC Capital Maintains Sector Perform on BioMarin Pharmaceutical, Lowers Price Target to $60 RBC Capital analyst Luca Issi maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price target from $62 to $60.
benzinga.com Stifel Maintains Hold on BioMarin Pharmaceutical, Lowers Price Target to $66 Stifel analyst Paul Matteis maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Hold and lowers the price target from $70 to $66.
benzinga.com Biomarin Pharmaceutical Q3 2026 Earnings Call Transcript Biomarin Pharmaceutical (NASDAQ:BMRN) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Biomarin Pharmaceutical Q3 Adj. EPS $0.23 Beats $0.12 Estimate, Sales $1.025B Miss $1.026B Estimate Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.12 by 91.67 percent. This is a 91.67 percent increase over…
benzinga.com BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 Est; Lowers FY2026 Sales Guidance from $3.875B-$3.925B to $3.800B-$3.900B vs $3.918B Est BioMarin Pharmaceutical (NASDAQ:BMRN) lowers FY2026 Adj EPS guidance from $4.90-$5.10 to $2.80-$3.10 vs $3.32 analyst estimate. Lowers FY2026 sales outlook from $3.875 billion-$3.925 billion to…- benzinga.com BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential…
benzinga.com Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122 Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.- benzinga.com Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
- benzinga.com Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114 Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.